Vistagen New Patents for the Treatment of Migraine

 Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone-free investigational pherine nasal spray in development as a rapid-onset treatment for vasomotor symptoms (hot flashes) due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea, and migraine.

The new patents complement previously granted PH80 U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for the treatment of migraine. All of the new patents are expected to be in effect until 2040, subject to possible patent term extensions on a country-by-country basis.

• Australia: IP Australia issued a Notice of Allowance;
• Hong Kong: The Hong Kong Special Administrative Region – Intellectual Property Department issued Patent No. 40068177;
• Japan: The Japan Patent Office issued Patent No. 7476229; and
• Mexico: The Mexican Institute of Industrial Property issued a Notice of Allowance.

https://www.biospace.com/article/releases/vistagen-broadens-ph80-global-intellectual-property-portfolio-with-new-patents-for-the-treatment-of-migraine/